8-K 1 form8k.htm FORM 8K form8k.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  April 2, 2008

Urigen Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)


Delaware
  
0-22987
  
94-3156660
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification
No.)
 
 
875 Mahler Road, Suite 235, Burlingame, California
  
94010
(Address of principal executive offices)
  
(Zip Code)
 
 
Registrant’s telephone number, including area code:  (650) 259-0239
 

(Former name or former address, if changed since last report)

Copies to:
Marc Ross, Esq.
Thomas Rose, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10018
Phone: (212) 930-9700
Fax: (212) 930-9725


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

/_/ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

/_/ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

/_/ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

/_/ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
Item 1.02. Termination of a Material Definitive Agreement.

On April 2, 2008 the Development and License Agreement between Urigen Pharmaceuticals, Inc. (the “Company”) and M&P Patent AG dated November 20, 2007 was terminated. The Agreement was terminated pursuant to the terms of section 11.3 which provided for termination of the Agreement with immediate effect if the initial milestone payment required by Section 5.1(ii) of the Agreement was not paid on or before April 1, 2008.

            The Company has taken this decision to focus its development efforts and resources on URG101, its development program targeting Painful Bladder Syndrome and to accelerate the development of URG300, its female urethral suppository platform. Given the recent positive interim analysis results of its URG101-104 Phase II clinical trial and the limited personnel and resources of the Company currently has available, management believed it was the appropriate time to focus on its URG 101 and URG300 products.


 
 
2
 


 




SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the Undersigned, thereunto duly authorized.
 
 
  Urigen Pharmaceuticals, Inc.  
       
Date April 8, 2008
By:
/s/ William J. Garner  
    Name William J. Garner, MD  
    Title President and Chief Executive Officer  
       

 
 
3